Climb Bio

Climb Bio Inventory Turnover

Inventory Turnover Ratio of Climb Bio (CLYM) as of Oct 17, 2026.

Inventory Turnover

-

Last updated:

Inventory Turnover Ratio of Climb Bio is 2026 - . Inventory Turnover Ratio of Climb Bio was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Climb Bio Stock analysis

What does Climb Bio do? Climb Bio Inc, headquartered in Wilmington, Delaware, is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders. The company, which went public on August 10, 2021, employs 30 full-time staff and is advancing a pipeline of product candidates targeting validated mechanisms for conditions including epilepsy, chronic pain, and psychiatric disorders. Its lead program, ETX-123, aims to improve safety and tolerability of Kv7.2/3 potassium channel openers. Climb Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Climb Bio stock

On Eulerpool you can find the complete historical development of Inventory Turnover Ratio Climb Bio since 2006 – with annual values, charts, and detailed analysis.

Inventory turnover measures how many times inventory is sold and replaced during a period. Higher turnover indicates efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory Turnover Ratio's Climb Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Climb Bio

All Key Metrics — Climb Bio